STOCK TITAN

Eloxx Pharmaceuticals Q3 2026 net loss widens to $5.54M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Eloxx Pharmaceuticals, Inc. (ELOX) reported a third-quarter 2026 net loss of $5.543 million, compared with a $0.351 million net loss in the same quarter of 2025. For the first nine months of 2026, net loss was $13.799 million versus $3.951 million a year earlier. Third-quarter research and development expenses were $4.028 million, compared with a $0.250 million net credit in 2025, while general and administrative expenses were $1.925 million versus $0.535 million.

Cash and cash equivalents were $56.264 million as of September 30, 2026, compared with $62.0 million as of June 30, 2026. Eloxx said it believes its cash will be sufficient to fund operations into 2028.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Funding outlook: Eloxx believes cash will fund operations into 2028.

Negative

  • Moderate pointQuarterly net loss: $5.543 million, versus $0.351 million in 2025.

Filing Explained

Eloxx’s update places its two disclosed rare-kidney-disease programs at different stages: the Phase 2b EXACT study has dosed its first two patients, while the EXPRESS study has IND clearance and a finalized protocol.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net loss $5.543 million Three months ended September 30, 2026; compared with a $0.351 million net loss in 2025.
Nine-month net loss $13.799 million Nine months ended September 30, 2026; compared with a $3.951 million net loss in 2025.
Research and development expenses $4.028 million Three months ended September 30, 2026; compared with a $0.250 million net credit in 2025.
General and administrative expenses $1.925 million Three months ended September 30, 2026; compared with $0.535 million in 2025.
Cash and cash equivalents $56.264 million As of September 30, 2026; compared with $62.0 million as of June 30, 2026.
Phase 2b EXACT study medical
"dosed the first two patients in our Phase 2b EXACT study"
IND clearance regulatory
"With the EXPRESS protocol finalized and IND clearance in hand"
IND clearance is regulatory authorization that allows a company to begin testing an experimental drug in human clinical trials. Think of it as a safety-passport from regulators confirming enough preclinical evidence exists to move from lab work to people; for investors it marks a major development milestone that de-risks the program’s path to approval, unlocks value-driving data milestones, and often influences funding, partnerships, and stock value.
readthrough of premature stop codons technical
"promote readthrough of premature stop codons"
nonsense mutation Alport syndrome medical
"treatment of rare kidney diseases, including nonsense mutation Alport syndrome"
Alport syndrome caused by a 'nonsense' mutation is a form of the inherited kidney disorder in which a single-letter change in a relevant gene creates an early stop signal, producing a shortened, nonfunctional protein involved in kidney, ear, and eye structure. It matters to investors because the mutation type affects how severe the disease is, which patients qualify for specific genetic tests or mutation-targeted treatments, and therefore the size and focus of related diagnostic and drug markets — like a factory blueprint cut short, creating a distinct subgroup with predictable needs.
autosomal dominant polycystic kidney disease medical
"nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease"
A hereditary kidney disorder in which fluid-filled sacs (cysts) form and grow on the kidneys, often caused when a single parent passes down a faulty gene. Over time the cysts can reduce kidney function and lead to serious health care needs, making it important to investors because it drives demand for diagnostic tests, drugs, medical devices and long-term care, and influences clinical trial activity and regulatory milestones.
Net loss $5.543 million Compared with a $0.351 million net loss in the same period of 2025.
Research and development expenses $4.028 million Compared with a $0.250 million net credit in the same period of 2025.
General and administrative expenses $1.925 million Compared with $0.535 million in the same period of 2025.
Cash and cash equivalents $56.264 million Compared with $62.0 million as of June 30, 2026.
Guidance

Eloxx believes its cash and cash equivalents will be sufficient to fund operations into 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was ELOX’s net loss in Q3 2026?

Eloxx reported a $5.543 million net loss for the three months ended September 30, 2026, compared with a $0.351 million net loss for the same period in 2025. For the first nine months of 2026, net loss was $13.799 million, versus $3.951 million in 2025.

How much cash did ELOX report at September 30, 2026?

Eloxx reported $56.264 million in cash and cash equivalents as of September 30, 2026. The company said it believes cash and cash equivalents will be sufficient to fund operations into 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NASDAQ false 0001035354 0001035354 2026-11-16 2026-11-16
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Eloxx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-31326   84-1368850

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

P.O. Box 274

10 Court Street, Arlington, MA 02476

(Address of principal executive offices, including zip code)

(781) 577-5300

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   ELOX   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 2.02.

Results of Operations and Financial Condition.

On November 16, 2026, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

  

Exhibit Description

99.1    Press release of Eloxx Pharmaceuticals, Inc.
104    Cover Page Interactive Data File (embedded within Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026   ELOXX PHARMACEUTICALS, INC.
    By:  

/s/ Sumit Aggarwal

    Name:   Sumit Aggarwal
    Title:   President and Chief Executive Officer

Exhibit 99.1

 

LOGO

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

 

  •  

Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expected in mid-2027

 

  •  

Finalized protocol and received IND clearance for Phase 2 EXPRESS study of exaluren in nonsense mutation autosomal dominant polycystic kidney disease (ADPKD); first patient expected to be dosed in the third quarter of 2027

 

  •  

Expanded leadership team with appointment of T.R. Srinivas, M.D., as SVP, Chief Medical Officer

 

  •  

Cash and cash equivalents of $56.3 million as of September 30, 2026

ARLINGTON, Mass., November 16, 2026 — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease,” said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Recent Business Highlights

 

  •  

Phase 2b EXACT study in nonsense mutation Alport syndrome (NMAS)

 

  •  

In September 2026, the Company announced that the first two patients had been dosed in its Phase 2b EXACT study (NCT07523581), a global, randomized, placebo-controlled, delayed-start trial of exaluren designed to enroll 24 patients with Alport syndrome caused by nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes. The primary efficacy endpoint of the initial 16-week placebo-controlled portion of the trial is the change in podocyte foot process effacement, measured as the change in filtration slit density on kidney biopsies, in non-U.S. pediatric patients and all adult patients.

 

  •  

An earlier open-label Phase 2a study observed structural improvements, including reduced foot process effacement and improved GBM width, in kidney biopsies in all three participants.

 

  •  

The Company expects to report topline data from the 16-week placebo-controlled portion in mid-2027 and final 32-week data by the end of 2027.

 

  •  

Phase 2 EXPRESS study in nonsense mutation ADPKD (nmADPKD)

 

  •  

The Company finalized the design of the 52-week EXPRESS study. EXPRESS is designed as a global, randomized, placebo-controlled trial in approximately 60 adults with genetically confirmed nonsense mutations in the PKD1 or PKD2 genes, who will be randomized 1:1 to receive exaluren or placebo for 52 weeks. The primary endpoint is the annualized rate of change in height-adjusted total kidney volume (htTKV), as measured by magnetic resonance imaging. Eloxx estimates that 40,000 to 50,000 people in the United States have ADPKD caused by nonsense mutations.


  •  

On October 29, 2026, the Company announced FDA clearance of the IND for exaluren in nmADPKD, enabling it to open U.S. clinical sites.

 

  •  

The Company expects to dose the first patient in the third quarter of 2027 and to report 52-week topline data in the first half of 2029. In pre-IND feedback reported by Eloxx in October, FDA indicated that a substantial and durable effect on kidney volume growth, with supporting kidney function and safety data, could be a potential basis for Breakthrough Therapy Designation. Any designation would depend on the clinical results and further FDA review.

 

  •  

Expanded leadership team and Board of Directors

 

  •  

In October 2026, the Company appointed T.R. Srinivas, M.D., as Senior Vice President and Chief Medical Officer, responsible for leading its renal medical strategy across its Alport syndrome and ADPKD programs. Dr. Srinivas joined Eloxx from Novartis, where he held U.S. Medical Affairs leadership responsibilities for ADPKD product development.

 

  •  

Also in October 2026, the Company’s Board of Directors appointed Geno Germano as a director, effective October 19, 2026. Mr. Germano brings more than 35 years of biopharmaceutical development and commercialization leadership. He most recently served as President and Chief Executive Officer of Elucida Oncology, and previously served as President of Intrexon (now Precigen) and as Group President of Pfizer’s Global Innovative Pharmaceutical business. He currently serves as Chairman of Entera Bio and as a director of Precision BioSciences and Harmony Biosciences and has previously served on the boards of Sage Therapeutics, Bioverativ, The Medicines Company and Zoetis.

Third Quarter 2026 Financial Results

In May 2026, the Company effected a one-for-eleven reverse stock split of its common stock and reduced its authorized shares of common stock from 500,000,000 to 100,000,000. All share and per-share amounts in this press release reflect the reverse stock split.

Research and development (R&D) expenses were $4.0 million for the three months ended September 30, 2026, compared to a net credit of $0.3 million for the same period in 2025. The increase was primarily related to higher clinical trial expenses associated with the initiation of the Phase 2b EXACT study, as well as increases in personnel costs. R&D expenses for the third quarter of 2025 were reduced by a $0.9 million write-off of accounts payable balances with certain vendors under settlement agreements.

General and administrative (G&A) expenses were $1.9 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025. The increase was primarily related to higher professional and consulting fees, including legal, audit and tax fees, increased personnel costs, and higher facility and other overhead costs.

Other income, net was $0.4 million for the three months ended September 30, 2026, compared to other expense, net, of $0.1 million for the same period in 2025. The change was primarily related to higher interest income on increased cash balances following the June 2026 public offering and lower interest expense.

Net loss for the three months ended September 30, 2026, was $5.5 million, or $(0.49) per share, which included $0.2 million in stock-based compensation, compared to a net loss of $0.4 million, or $(0.58) per share, for the same period in 2025. For the nine months ended September 30, 2026, net loss was $13.8 million, or $(1.83) per share, compared to $4.0 million, or $(9.12) per share, for the same period in 2025.


Cash position. As of September 30, 2026, the Company had cash and cash equivalents of $56.3 million, compared to $62.0 million as of June 30, 2026. The Company believes its cash and cash equivalents will be sufficient to fund its operations into 2028.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx’s lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.

For more information, please visit www.eloxxpharma.com. The corporate presentation and investor event information are available at www.eloxxpharma.com/investors/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including, without limitation, statements regarding the sufficiency of the Company’s cash and cash equivalents to fund its operations; the expected timing of enrollment in, and topline and final data from, the Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; the expected timing of initiation of, and topline data from, the planned Phase 2 EXPRESS study of exaluren in nonsense mutation ADPKD; the potential for exaluren to receive Breakthrough Therapy Designation or to be eligible for accelerated approval or other expedited regulatory pathways; the potential benefits of orphan drug designation; the Company’s ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; the Company’s collaboration with Almirall and the potential to receive milestone and royalty payments; and the potential of the Company’s product candidates to treat diseases caused by nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as “aim,” “may,” “will,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “potential,” “seeks,” or “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited to, the Company’s need for and ability to obtain additional capital; the uncertainty of timing, results and expense related to the clinical and regulatory development process; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future results; and other important factors discussed under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and elsewhere in the Company’s filings with the SEC, accessible on the SEC’s website at www.sec.gov and on the “Financials & Filings” page of the Company’s website. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.

Contact

Investor Relations

Eloxx Pharmaceuticals, Inc.

ir@eloxxpharma.com

(781) 577-5300


ELOXX PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

 

     Three Months Ended     Nine Months Ended  
     September 30,     September 30,  
     2026     2025     2026     2025  

Operating expenses:

        

Research and development

   $ 4,028     $ (250 )    $ 8,528     $ 1,158  

General and administrative

     1,925       535       5,671       1,931  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     5,953       285       14,199       3,089  

Loss from operations

     (5,953 )      (285 )      (14,199 )      (3,089 ) 

Other (income) expense, net

     (410 )      66       (400 )      862  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (5,543 )    $ (351 )    $ (13,799 )    $ (3,951 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share, basic and diluted

   $ (0.49 )    $ (0.58 )    $ (1.83 )    $ (9.12 ) 
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic and diluted

     11,404,791       604,278       7,551,283       433,358  

ELOXX PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheet Data

(in thousands)

(2026 unaudited)

 

     September 30,      December 31,  
     2026      2025  

Cash and cash equivalents

   $ 56,264      $ 4,785  

Total assets

   $ 58,261      $ 5,270  

Total current liabilities

   $ 17,192      $ 17,177  

Total stockholders’ equity (deficit)

   $ 41,069      $ (11,907 ) 

Filing Exhibits & Attachments

4 documents

Keep reading